Pancreatic Cancer Research

ResearcherHarvard UniversityNo recent work listed

Jason Edward Faris

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5015900819. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
59
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper

Papers 9

  1. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical… Co-author DOI 10.1001/jamaoncol.2019.0892↗
  2. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical … Co-author DOI 10.1001/jamaoncol.2018.0329↗
  3. Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Ca… Co-author DOI 10.1097/coc.0000000000000349↗
  4. A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing … Co-author DOI 10.1007/s10637-017-0473-9↗
  5. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Co-author DOI 10.1016/s1470-2045(16)00172-8↗
  6. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1097/sla.0000000000000867↗
  7. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Co-author DOI 10.1634/theoncologist.2012-0435↗
  8. The controversial role of chemoradiation for patients with locally advanced pancreatic cancer. Co-author DOI 10.1634/theoncologist.2013-0270↗
  9. A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. Co-author DOI 10.1007/s10637-011-9708-3↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jennifer Yon-Li Wo · 6 shared papers, 2013–2019 · strength 0.34
  2. Theodore Sunki Hong · 6 shared papers, 2013–2019 · strength 0.30
  3. David P. Ryan · 6 shared papers, 2012–2019 · strength 0.29
  4. Lawrence Scott Blaszkowsky · 6 shared papers, 2012–2019 · strength 0.29
  5. Eunice Lee Kwak · 6 shared papers, 2012–2019 · strength 0.29
  6. Janet E. Murphy · 5 shared papers, 2013–2019 · strength 0.26
  7. Cristina Rosa Ferrone · 5 shared papers, 2013–2019 · strength 0.26
  8. Keith D. Lillemoe · 5 shared papers, 2013–2019 · strength 0.26
  9. Carlos F. Fernandez-del Castillo · 3 shared papers, 2015–2018 · strength 0.17
  10. Ryan David Nipp · 2 shared papers, 2018–2019 · strength 0.13
  11. David Tsai Ting · 2 shared papers, 2015–2019 · strength 0.10
  12. Carlos Fernández-del Castillo · 2 shared papers, 2013–2019 · strength 0.09
  13. Rakesh K. Jain · 1 shared paper, 2019 · strength 0.06
  14. Yves Boucher · 1 shared paper, 2019 · strength 0.06
  15. Nilesh P. Talele · 1 shared paper, 2019 · strength 0.06
  16. Motaz Qadan · 1 shared paper, 2019 · strength 0.06
  17. Aparna R. Parikh · 1 shared paper, 2019 · strength 0.06
  18. Dan Gabriel Duda · 1 shared paper, 2019 · strength 0.06
  19. Ryan Bruce Corcoran · 1 shared paper, 2019 · strength 0.06
  20. Colin D. Weekes · 1 shared paper, 2019 · strength 0.06
  21. Thea Kalebic · 1 shared paper, 2017 · strength 0.05
  22. Khaldoun Almhanna · 1 shared paper, 2017 · strength 0.05
  23. Jean‐Luc Van Laethem · 1 shared paper, 2017 · strength 0.05
  24. Naureen Starling · 1 shared paper, 2017 · strength 0.05
  25. Carmen Guillén‐Ponce · 1 shared paper, 2017 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.